These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28991932)

  • 121. Diabetes News.
    Dove AE; Marathe PH; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Feb; 9(2):111-114. PubMed ID: 27763720
    [No Abstract]   [Full Text] [Related]  

  • 122. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.
    McIntyre RS
    Expert Opin Drug Saf; 2024 May; 23(5):539-542. PubMed ID: 38520274
    [No Abstract]   [Full Text] [Related]  

  • 123. Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
    Versmissen J
    Neth J Med; 2014 Dec; 72(10):507-8. PubMed ID: 26219754
    [No Abstract]   [Full Text] [Related]  

  • 124. Lixisenatide: first global approval.
    Elkinson S; Keating GM
    Drugs; 2013 Mar; 73(4):383-91. PubMed ID: 23558600
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Time to unshackle the medical treatment of obesity in the NHS.
    Ansari S; Mazaheri T; O'Donnell K; Waite M; Cann A; Abdel-Malek M; Boyle L; Tweedlie L; Scholtz S; Hameed S; Izzi-Engbeaya C; Chahal H; Tan T
    Clin Med (Lond); 2024 May; 24(3):100206. PubMed ID: 38643826
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.
    Abdelmannan D; AlBuflasa M; Ajlouni H; Zidan M; Rahman F; Farooqi MH; Enrique Caballero A
    Diabetes Res Clin Pract; 2024 Jan; 207():111045. PubMed ID: 38070546
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
    Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
    BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.
    Yammine L; Balderas JC; Weaver MF; Schmitz JM
    J Addict Med; 2023 Jul-Aug 01; 17(4):481-484. PubMed ID: 37579116
    [TBL] [Abstract][Full Text] [Related]  

  • 129. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 130. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
    Salvador J; Andrada P
    Med Clin (Barc); 2014; 143 Suppl 2():28-34. PubMed ID: 25326841
    [TBL] [Abstract][Full Text] [Related]  

  • 131. A new indication for semaglutide (Wegovy).
    Med Lett Drugs Ther; 2024 Apr; 66(1701):66-67. PubMed ID: 38691645
    [No Abstract]   [Full Text] [Related]  

  • 132. What the SELECT trial of semaglutide means for clinicians.
    Sattar N; Lee MMY; McGuire DK
    Nat Med; 2024 Jul; 30(7):1830-1831. PubMed ID: 38796654
    [No Abstract]   [Full Text] [Related]  

  • 133. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
    Camilleri M; Carlson P; Dilmaghani S
    Obesity (Silver Spring); 2024 Feb; 32(2):232-233. PubMed ID: 37927173
    [No Abstract]   [Full Text] [Related]  

  • 134. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
    BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.
    Chandrashekar C; Lin F; Nishiuchi Y; Mohammed SF; White BF; Arsenakis Y; Yuliantie E; Zhao P; van Dun S; Koijen A; Kajihara Y; Wootten D; Dodd GT; van den Bos LJ; Wade JD; Hossain MA
    J Med Chem; 2024 May; 67(9):7276-7282. PubMed ID: 38465973
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 137. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 138. Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
    Herrington WG; Haynes R
    N Engl J Med; 2024 Jul; 391(2):178-179. PubMed ID: 38986062
    [No Abstract]   [Full Text] [Related]  

  • 139. Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.
    Du J; Xi L; Zhang Z; Ge X; Li W; Peng W; Jiang X; Liu W; Zhao N; Wang X; Guo X; Huang S
    Front Endocrinol (Lausanne); 2022; 13():1097612. PubMed ID: 36686441
    [TBL] [Abstract][Full Text] [Related]  

  • 140. An alternative combination therapy for type 2 diabetes?
    Østoft SH; Christensen M
    Lancet; 2015 May; 385(9982):2020-2. PubMed ID: 26009215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.